Drug survival of biologic therapy in a large, disease‐based registry of patients with psoriasis: results from the Psoriasis Longitudinal Assessment and Registry (PSOLAR)

BACKGROUND: Drug survival is a marker for treatment sustainability in chronic diseases such as psoriasis. OBJECTIVE: The aim of these analyses was to assess survival of biologic treatments in the PSOriasis Longitudinal Assessment and Registry (PSOLAR). METHODS: PSOLAR is a large, prospective, intern...

Descripción completa

Detalles Bibliográficos
Autores principales: Menter, A., Papp, K.A., Gooderham, M., Pariser, D.M., Augustin, M., Kerdel, F.A., Fakharzadeh, S., Goyal, K., Calabro, S., Langholff, W., Chavers, S., Naessens, D., Sermon, J., Krueger, G.G.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2016
Materias:
Original Articles and Short Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5071685/
https://www.ncbi.nlm.nih.gov/pubmed/27027388
http://dx.doi.org/10.1111/jdv.13611

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5071685/
https://www.ncbi.nlm.nih.gov/pubmed/27027388
http://dx.doi.org/10.1111/jdv.13611

Ejemplares similares